CSRxP Statement on CMS Changes to Medicare Part B

See more

High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma

See more

I-MAK Report Demonstrates Big Pharma's Abuses of the Patent System

See more

Lilly & Biogen Q2 Earnings Show That the Problem is the Price

See more

CSRxP Applauds Trump Administration's Focus on Drug Prices

See more

CSRxP Applauds FDA's Biosimilars Action Plan

See more

CSRxP Comments on the Blueprint to Lower Drug Prices

See more

CSRxP Statement on Celgene's Revlimid Price Hike

See more
Want to learn more? Let us know how to reach you for updates.


WHAT CAN HIGH DRUG PRICES DO TO US?
  • Threaten access to care
  • Raise out of pocket costs
  • Create higher premiums
  • Raise taxes
  • Threaten care infrastructure
Need More info?
Please reach out to us with any questions.

Contact Us

  • U.S. spending on prescription drugs saw the largest increase since 2001, with the nation’s pharmacy bill rising to $373.9 billion last year as new treatments came to market and manufacturers increased prices on old ones.

  • "There are no multiple sclerosis drugs available in the United States with a list price below $50,000 a year"

  • For the price of Sovaldi for one patient, we could provide health insurance through Medicaid for [up to] 26 people for an entire year.

  • [Solvadi's price] has the potential to throw a wrench into short-term state budgets.

Learn more about how you can help bring reasonable drug prices to this country.

Contact Us